PARP inhibitory therapy of acute ischemic stroke

PARP抑制治疗急性缺血性脑卒中

基本信息

项目摘要

DESCRIPTION (provided by applicant): Stroke activates the nuclear enzyme poly (ADP-ribose) polymerase ("PARP"), triggering cells to undergo necrosis and inflammation. Inotek's ultrapotent clinical PARP inhibitor ("INO-1001') profoundly reduces tissue necrosis and neurologic dysfunction in transient and permanent ischemic rat stroke models. Our data are in agreement with genetic deletion studies in stroked mice, which demonstrate > 80% neuroprotection in MCA occlusion models. We now propose a clinical study of INO-1001 to confirm tolerability, pharmacokinetics, and safety in a population with acute stroke. Based on clinical studies of INO-1001 in healthy subjects, we expect that INO-1001 will be Well-tolerated and safe, and maintain therapeutic drug plasma concentrations for 24 hours after a single bolus. We will test this hypothesis by carrying out a prospective, open-label multi-center study of n=30 subjects presenting with a clinical diagnosis and CT confirmation of acute non-lacunar ischemic stroke. A dose-escalation is planned, structured in cohorts of n=10 subjects per dose level. Subjects will be continuously monitored and observed for alterations in vital signs, physical exam, electrocardiogram, metabolic status, and clinical chemistries, hematologic and coagulation parameters, and plasma drug concentration. Whilst clinical outcome will be recorded, this is not intended to be a therapeutic trial, and wall include stable patients, who are able to consent themselves and report symptoms, with more detailed pharmacokinetic and tolerability monitoring than would be typical in a large multi-center investigation of efficacy. In a follow-on Phase 2 SBIR, we will carry out a pivotal study of INO-1001 in 900 patients to establish efficacy in a population with acute non-lacunar ischemic stroke. We will assess the effect of INO-1001 on 1) brain infarction, as quantitated by MRI, and 2) neurologic dysfunction, as assessed at baseline, 4 days, I week, 2 weeks, and I month by (a) NIHSS modified Rankin and Barthel score.
描述(申请人提供):中风激活核酶多聚(ADP-核糖)聚合酶(“PARP”),触发细胞发生坏死和炎症。伊诺克的超强临床PARP抑制剂(“INO-1001‘)可显著减少短暂性和永久性脑缺血大鼠中风模型中的组织坏死和神经功能障碍。我们的数据与中风小鼠的基因缺失研究一致,该研究表明在大脑中动脉闭塞模型中有80%的神经保护。我们现在提议进行一项临床研究,以证实INO-1001在急性中风人群中的耐受性、药代动力学和安全性。 基于INO-1001在健康人中的临床研究,我们预计INO-1001将是 耐受性良好且安全,并在服药后24小时内保持治疗药物的血药浓度 单次推注。我们将通过开展一项前瞻性的开放标签多中心研究来检验这一假设 30例有临床诊断和CT证实的急性非腔隙病变患者 缺血性中风。计划进行剂量递增,每个剂量水平n=10名受试者组成队列。 将持续监测和观察受试者的生命体征、体检、 心电图、代谢状态、临床化学、血液学和凝血 参数和血药浓度。虽然临床结果将被记录下来,但这不是 旨在作为一项治疗试验,而WALL包括能够同意自己的稳定患者 并报告症状,进行更详细的药代动力学和耐受性监测 在大型多中心疗效研究中具有典型性。在后续的第二阶段SBIR中,我们将进行 在900名患者中进行了一项关键研究,以确定INO-1001在急性白血病人群中的疗效 非腔隙性缺血性卒中。我们将评估INO-1001对脑梗塞的影响,因为 2)神经功能障碍,如在基线、4天、1周、2周、 I个月按(A)NIHSS修正的Rankin和Barthel评分。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREW Lurie SALZMAN其他文献

ANDREW Lurie SALZMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREW Lurie SALZMAN', 18)}}的其他基金

Treatment of congenital heart disease associated pulmonary hypertension
先天性心脏病相关肺动脉高压的治疗
  • 批准号:
    8831801
  • 财政年份:
    2015
  • 资助金额:
    $ 43.42万
  • 项目类别:
A Novel Immunotolerizing Therapy for Autoimmune Vitiligo
一种治疗自身免疫性白癜风的新型免疫耐受疗法
  • 批准号:
    8713488
  • 财政年份:
    2014
  • 资助金额:
    $ 43.42万
  • 项目类别:
Restoration of free radical homeostasis: novel therapy of septic shock
恢复自由基稳态:感染性休克的新疗法
  • 批准号:
    9342949
  • 财政年份:
    2012
  • 资助金额:
    $ 43.42万
  • 项目类别:
Resuscitation of smoke inhalation and burn injury with a thioredoxin mimetic
用硫氧还蛋白模拟物复苏烟雾吸入和烧伤
  • 批准号:
    8338756
  • 财政年份:
    2012
  • 资助金额:
    $ 43.42万
  • 项目类别:
A Redox-active PARP Inhibitor for Lung Transplantation
用于肺移植的氧化还原活性 PARP 抑制剂
  • 批准号:
    8391286
  • 财政年份:
    2012
  • 资助金额:
    $ 43.42万
  • 项目类别:
Restoration of free radical homeostasis: novel therapy of septic shock
恢复自由基稳态:感染性休克的新疗法
  • 批准号:
    9140177
  • 财政年份:
    2012
  • 资助金额:
    $ 43.42万
  • 项目类别:
Bifunctional Redox Catalyst & Organic Nitrate for Limb Reperfusion
双功能氧化还原催化剂
  • 批准号:
    8522327
  • 财政年份:
    2011
  • 资助金额:
    $ 43.42万
  • 项目类别:
PARP inhibition for thoraco-abdominal aneurysm surgery
PARP 抑制在胸腹动脉瘤手术中的应用
  • 批准号:
    6933563
  • 财政年份:
    2005
  • 资助金额:
    $ 43.42万
  • 项目类别:
PARP inhibitor therapy for septic shock
PARP 抑制剂治疗感染性休克
  • 批准号:
    6790412
  • 财政年份:
    2004
  • 资助金额:
    $ 43.42万
  • 项目类别:
Inosine pro-drug: novel therapy for arthritis
肌苷前药:关节炎的新疗法
  • 批准号:
    6867616
  • 财政年份:
    2003
  • 资助金额:
    $ 43.42万
  • 项目类别:

相似海外基金

FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
  • 批准号:
    EP/Y036395/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.42万
  • 项目类别:
    Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
  • 批准号:
    10764456
  • 财政年份:
    2023
  • 资助金额:
    $ 43.42万
  • 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 43.42万
  • 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
  • 批准号:
    10743328
  • 财政年份:
    2023
  • 资助金额:
    $ 43.42万
  • 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
  • 批准号:
    10638813
  • 财政年份:
    2023
  • 资助金额:
    $ 43.42万
  • 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
  • 批准号:
    10823828
  • 财政年份:
    2023
  • 资助金额:
    $ 43.42万
  • 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
  • 批准号:
    10828665
  • 财政年份:
    2023
  • 资助金额:
    $ 43.42万
  • 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
  • 批准号:
    10721095
  • 财政年份:
    2023
  • 资助金额:
    $ 43.42万
  • 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
  • 批准号:
    10795328
  • 财政年份:
    2023
  • 资助金额:
    $ 43.42万
  • 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
  • 批准号:
    10828252
  • 财政年份:
    2023
  • 资助金额:
    $ 43.42万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了